HLB's liver cancer drug extends survival to 23.8 months
HLB revealed the Phase 3 clinical trial in the United States, saying the median overall survival (mOS) for patients treated with its liver cancer drug has been extended to 23.8 months from 22.1 months, the company said Tuesday.
